Articles published in Metabolomics:Open Access have been cited by esteemed scholars and scientists all around the world.
Metabolomics:Open Access has got h-index 14, which means every article in Metabolomics:Open Access has got 14 average citations.
Following are the list of articles that have cited the articles published in Metabolomics:Open Access.
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
Year wise published articles |
20 | 30 | 24 | 7 | 9 |
Year wise citations received |
102 | 110 | 105 | 105 | 96 |
| Journal total citations count | 895 |
| Journal impact factor | 1.8 |
| Journal 5 years impact factor | 3.73 |
| Journal cite score | 2.25 |
| Journal h-index | 14 |
| Journal h-index since 2018 | 9 |
Lu DY, Lu TR (2014) Innovations in Pharmaceuticals and Pharmacotherapy. IPP 2: 458-469. |
|
Smith AJ, Oertle J, Warren D, Prato D (2016) Chimeric antigen receptor (CAR) T cell therapy for malignant cancers: Summary and perspective. Journal of Cellular Immunotherapy 2: 59-68. |
|
Lu DY, Chen EH, Wu HY, Lu TR, Xu B,et al. (2017) Anticancer drug combinations, how far we can go through?. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents)17: 21-8. |
|
Lu DY, Lu TR, Ding J, Xu B, Che JY, et al. (2015) Anticancer drug sensitivity testing, a historical review and future perspectives. Current Drug Therapy 10: 44-55. |
|
Lu DY, Lu TR, Xu B, Ding J (2015) Pharmacogenetics of cancer therapy: breakthroughs from beyond?. Future Science OA 1. |
|
Lu DY, Lu TR, Chen XL, Chen EH, Ding J, et al. (2015)Cancer bioinformatics, its impacts on cancer therapy. Metabolomics 5: e133. |
|
Lu DY, Lu TR, Wu HY (2014) Personalized cancer therapy, a perspective. Clin Exp Pharmacol 4:153. |
|
Lu DY, Lu TR, Wu HY (2013) New insights into individualized antimetastatic therapy. Advanced Techniques in Biology & Medicine |
|
Lu DY, Lu TR, Wu HY, Cao S (2013) Cancer Metastasis treatments. Current Drug Therapy 8: 24-29. |
|
Ivanov DD, Melnik AA (2016) Pharmacogenetic testing in a nephrologic clinic. The kidneysPp: 12-16. |
|
Cacabelos R, Torrellas C, López-Muñoz F (2016) Pharmacogenomics of Antidepressant Drugs. InMelatonin, Neuroprotective Agents and Antidepressant Therapy Springer India Pp: 545-609. |
|
Cacabelos R (2016) Epigenetics of Brain Disorders: The Paradigm of Alzheimer’s Disease. J Alzheimers Dis Parkinsonism 6: 2161-0460. |
|
Cacabelos R, Torrellas C, Teijido O, Carril JC (2016) Pharmacogenetic considerations in the treatment of Alzheimer's disease. Pharmacogenomics 17:1041-1074. |
|
Cacabelos R, Torrellas C, Cacabelos P, Villanueva MJ, Piñeiro S, at el. (2015) Pharmacogenetics of neurodegenerative disorders. InPreventive and Predictive Genetics: Towards Personalised Medicine Springer International Publishing pp: 173-240. |
|
Torrellas C, Carril JC, Cacabelos R (2014) Benefits of Pharmacogenetics in the Management of Hypertension. Journal of Pharmacogenomics & Pharmacoproteomics 5: 1. |
|
Cacabelos R (2015) Impact of genomic medicine on the future of Neuropsychopharmacology. J Neuropsychopharmacol Mental Health 1. |
|
Cacabelos R, Goldgaber D, Roses AD, Vostrov A, Matsuki H (2015) Gene interactions in the Pharmacogenomics of Alzheimer’s disease. Front Genet 1. |
|
Cacabelos R, Torrellas C, Carrera I (2015) Opportunities in pharmacogenomics for the treatment of Alzheimer's disease. Future Neurology 10: 229-252. |
|
Cacabelos R, Torrellas C (2015) Epigenetics of aging and Alzheimer’s disease: Implications for pharmacogenomics and drug response. International journal of molecular sciences 16: 30483-30543. |
|
Cacabelos R (2014) Epigenomic networking in drug development: from pathogenic mechanisms to pharmacogenomics. Drug development research 75: 348-365. |
|
Metabolomics:Open Access received 895 citations as per Google Scholar report
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 